Navigation Links
NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Date:10/30/2009

t of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently planning the design and timing of this program.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; plans and timing for commercialization of Qutenza; and development activities for NGX-1998 and other product candidates, including regulatory submissions and any outcomes of such submissions.
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX to Present at JMP Securities Healthcare Focus Conference
2. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
3. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
4. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
5. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
6. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
7. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
10. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
11. Beckman Coulter Announces Conference Call and Webcast of Accompanying Slides in Conjunction With Third Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 /CNW/ - A new expert ... Canada , released today by the ... safe and effective medicines for children. Each year about ... children use at least one prescription drug. Much of ... from the authorized use), creating potential health risks. ...
(Date:9/18/2014)... 18, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... focused on discovering, developing and commercializing innovative ... RNA-targeted technologies, today announced that the Company,s President ... Cauwenbergh , will present at the 7 ... Wednesday, September 24, 2014 at 11:20 a.m. ...
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
Breaking Medicine Technology:Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9
... , , ... external defibrillators used worldwide in health care facilities, public places, or in the home may ... Administration warned today. , , , ... , , ...
... STOCKHOLM , April 27, 2010 Axelar AB, ... been,elected new chairman of the board and Ingemar Kihlstrom board ... , , ... have just secured 25 MSEK financing for the continued development of,Axelar,s anticancer ...
Cached Medicine Technology:FDA Warns Users About Faulty Components in 14 External Defibrillator Models 2FDA Warns Users About Faulty Components in 14 External Defibrillator Models 3Axelar's Board Strengthened 2Axelar's Board Strengthened 3
(Date:9/18/2014)... This past August, Narconon Louisiana New Life Retreat ... kissing booth during the West Feliciana Animal Humane Society fundraiser to ... loved animals my whole life and have always had animals as ... who needed a home. Supporting an animal shelter allows me ... home!” , The CEO of Narconon Louisiana was there not only ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 Relias Learning, ... health and human services markets, today announced it has been ... fastest growing private companies in America. , In the three-year ... and moved up almost 2,000 spots on the Inc. 5000 ... 2012. , “The industries we serve continue to ...
(Date:9/18/2014)... September 18, 2014 The new ... boon to contractors and homeowners alike as it ... overtakes the home, causes potential health issues, and ... nationwide, the BuildClean system allows contractors to virtually ... and other standard remodeling tasks. , BuildClean removes ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, Sept. ... be associated with increased odds of developing Parkinson,s disease ... suggests. The study, which did not prove a ... that the migraine-Parkinson,s association was stronger in women with ... sign of a pending attack that includes flashes of ...
(Date:9/18/2014)... 2014 It is true that ... when building a successful brand or business online. ... has recently compared plenty of professional web hosting ... Arvixe and iPage are the best VPS hosting ... of web hosting. All-sized businesses or enterprises can ...
Breaking Medicine News(10 mins):Health News:Narconon New Life Retreat Supports Local Animal Shelter At Recent Fundraiser 2Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 2Health News:Are Migraines in Middle Age Tied to Raised Parkinson's Risk Later? 3Health News:Best Cheap Hosting USA: GreenGeeks, Arvixe And iPage Are The Best Hosting Suppliers In 2014 2
... Bolling Air Force Base in Washington D.C., as well as a lecture ... ... Washington, D.C. (Vocus) July 2, 2008 -- The Drug Enforcement Administration ... Richard Nixon, who through an Executive Order established a single unified command ...
... QuadraBloc™, a new and improved version of AmWay's MagnaBloc. , ... ... a long-popular form of pain management, is now available in a ... ,"QuadraBloc has already been released in the United States, and will ...
... will be October 24-26, 2008 at the Catholic Institute in Toulouse, ... knowledge, ideas, applications and prospective issues in an interactive and collaborative ... http://www.ifats08.org for details. , ... Carmel, IN (PRWEB) ...
... using a combination of drugs targeting different parts of ... with severe lupus involving the kidneys, according to a ... Society of Nephrology (JASN). , "In our study, ... therapy for inducing complete remission of class V+IV lupus ...
... Clearance of Uniquely Integrated Meter/Pump System with ... and Compatible Software, WEST CHESTER, Pa., July ... its OneTouch(R) Ping(TM) Glucose Management System,by the U.S. ... the first,full-feature insulin pump that wirelessly communicates with ...
... of 300 human genomes in just over six months. The ... of genetic code that will be read by researchers worldwide, ... and disease. Scientists will be able to answer questions unthinkable ... be transformed. , The amount of data is remarkable: ...
Cached Medicine News:Health News:New MagnaBloc™ Product Available from Gradient Medical 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 3Health News:'Multi-target' immune therapy improves outcomes of severe lupus nephritis 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 3Health News:15 human genomes each week 2Health News:15 human genomes each week 3
... 4.5x and 5.5x magnification., ,Higher magnification ... guarantees a true image. Edge to ... is ideal for intricate surgical applications. ... with an anti-reflective coating to produce ...
VACUETTE® Tube Holders should be used exclusively with VACUETTE® Blood Collection Needles as both components are designed for optimal compatibility with one another....
Inquire...
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Medicine Products: